Interferon

Type: Keyphrase
Name: Interferon
First reported 6 hours ago - Updated 6 hours ago - 1 reports

Spreading fast: Lack of treatment drug leaves patients helpless against hepatitis

Interf­eron vials worth Rs250 millio­n were purcha­sed for hospit­als but were found to be substa­ndard.The fortunate fighter credited his doctors for playing the lead role in his recovery, saying that they guided him through his treatment process without ... [Published The Express Tribune - 6 hours ago]
First reported 11 hours ago - Updated 11 hours ago - 1 reports

Sofosbuvir/ledipasvir reduced HCV-related liver complications

NEW YORK — The NS5A and NS5B inhibitors ledipasvir/sofosbuvir reduced the incidence of compensated and decompensated cirrhosis, hepatocellular carcinoma and liver transplant in patients with hepatitis C virus compared with sofosbuvir with pegylated interferon ... [Published Orthopedics Today - 11 hours ago]
First reported 12 hours ago - Updated 12 hours ago - 1 reports

Study Shows Type 1 Interferons Block Allergy and Asthma Driving Cells

Immunology research conducted at the University of Texas Southwestern Medical Center has found that type 1 interferons (IFNs) block the development of cells that drive allergies and asthma.According to work published in the June 2014 edition of The Journal ... [Published Pharmacy Times - 12 hours ago]
Entities: Interferon, Asthma, Allergy
First reported 18 hours ago - Updated 15 hours ago - 1 reports

Gilead to raise price for new hepatitis C drug | 2014-09-16 12:51:17 PM

The next generation version of Gilead Sciences Inc's $84,000 hepatitis C drug, already under fire for its record-breaking costs, is going to be even more expensive.Gregg Alton, Gilead's executive vice president of corporate and medical affairs, declined ... [Published Nile International - 18 hours ago]
First reported 21 hours ago - Updated 21 hours ago - 1 reports

Therapeutic agent for hematopoietic tumors

An inducing agent or enhancing agent, for the expression of HM1.24 antigen in hematopoietic tumor cells, comprising interferon α, interferon γ, or the IRF-2 protein as an active ingredient, as well as an antitumor agent for hematopoietic tumors which ... [Published Free Patents Online - 21 hours ago]
First reported Sep 15 2014 - Updated Sep 16 2014 - 2 reports

Access to new drugs could save 350 lives from hep C

Three hundred and fifty people seriously ill with hepatitis C need early access to new therapies that could save their lives, according to the Irish Haemophilia Society (IHS).Of the 12,365 patients in Ireland with hepatitis C, 350 need urgent treatme ... [Published Irish Examiner - Sep 16 2014]
First reported Sep 15 2014 - Updated Sep 16 2014 - 1 reports

Call for early access to Hep C treatments

The Irish Haemophilia Society has called for 350 seriously-ill people with the Hepatitis C virus to be given early access to new treatments that could save their lives.It says that this group can not medically tolerate the current Interferon treatment, ... [Published RTE Online - Sep 15 2014]
First reported Sep 16 2014 - Updated Sep 16 2014 - 1 reports

The Effects of Interferon/Ribavirin Therapy on Bone Turnover Markers (BTMs) in HIV/HCV Co-Infected Subjects

ICAAC 2014 54th Interscience Conferenceon Antimicrobial Agents and ChemotherapySeptember 5-9, 2014, Washington, DC from Jules: AS I would expect the simple explanation of the outcome of this study is that it suggests achieving an SVR improves bone health, ... [Published National AIDS Treatment Advocacy Project - Sep 16 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

T-bet tackles hepatitis

A single protein may tip the balance between ridding the body of a dangerous virus and enduring life-long chronic infection, according to a report appearing in The Journal of Experimental Medicine.Hepatitis B and C viruses cause chronic infections in ... [Published Medical Xpress - Sep 15 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 2 reports

Gilead’s New Sovaldi To Be Even More Expensive For US Patients

Gilead is expected to launch a newer, more "expensive" version of Sovaldi next month. The company is also entering licensing agreements with generic drug makers who will sell the drug at a lower price in developing countriesPage 1 of 3Click Ticker to ... [Published Bidness Etc - Sep 15 2014]
First reported Sep 12 2014 - Updated Sep 13 2014 - 2 reports

Gilead to price new hepatitis C drug above $84,000

The next generation version of Gilead Sciences Inc's $84,000 Hepatitis C drug , already under fire for its record-breaking costs, is going to be even more expensive. Gregg Alton, Gilead's executive vice president of corporateand medical affairs, declined ... [Published DNA India - Sep 13 2014]
First reported Sep 10 2014 - Updated Sep 11 2014 - 2 reports

Hemispherx and USAMRIID collaborate on Ebola virus infection studies

Hemispherx Biopharma, Inc. and US Army Medical Research Institute of Infectious Diseases, or USAMRIID, have agreed to study Alferon and Ampligen against the Ebola virus. Alferon is the only multi-species, natural alpha interferon (IFN) commercially approved ... [Published Individual.com - Sep 11 2014]

Quotes

“Children tolerate interferon better than adults tolerate it,” he says. "No one wants to over-treat, but the uncertainty (of a diagnosis) should be acknowledged and addressed head-on.”"
...com/Hepatology . "However, the other structural barriers beside costs and interferon side effects are still threatening the favorable targeted outcomes."   – by Melinda Stevens
...vitro through nucleic acid machinery that generally only allows linear DNA/RNA to be packaged through a portal channel," Liu tells Medical Xpress. "However, in vitro protein packaging is generally impossible, because for most viral nanoparticles there is no protein packaging machinery comparable to nucleic acid packaging machinery." While protein may be chemically cross-linked to the capsid inner surface, this is expected to lead to protein denaturation and loss of enzymatic act...
..."We are going to price this fixed-dose regimen based on those costs," Alton said. "We do plan on launching a better product without having a significant premium."

More Content

All (656) | News (512) | Reports (0) | Blogs (138) | Audio/Video (0) | Fact Sheets (3) | Press Releases (2)
sort by: Date | Relevance
Incidence of pediatric melanoma on the rise [Published Dermatology Times - 6 hours ago]
Spreading fast: Lack of treatment drug leaves p... [Published The Express Tribune - 6 hours ago]
Costs, lack of referrals hinder patient access ... [Published Orthopedics Today - 7 hours ago]
Indian drugmakers to bring cheap HCV drug Soval... [Published In-Pharmatechnologist - 11 hours ago]
Sofosbuvir/ledipasvir reduced HCV-related liver... [Published Orthopedics Today - 11 hours ago]
Anatomy of a Virus [Published The Scientist - 11 hours ago]
Study Shows Type 1 Interferons Block Allergy an... [Published Pharmacy Times - 12 hours ago]
Nanocontainers for nanocargo: Delivering genes ... [Published PhysOrg.com - 12 hours ago]
CAR T Cells: A Look Under the Hood and Down the... [Published General Medicine eJournal - 13 hours ago]
Global Infections Caused By Picornaviridae Ther... [Published Individual.com - 15 hours ago]
DNAtrix Announces Treatment Of First Patient Wi... [Published PR Newswire: Health - 16 hours ago]
Gilead to raise price for new hepatitis C drug ... [Published Nile International - 18 hours ago]
Update on Alnylam (And the Direction of Things ... [Published In the Pipeline - 18 hours ago]
Therapeutic agent for hematopoietic tumors [Published Free Patents Online - 21 hours ago]
Daclizumab HYP a new kid on the block [Published Multiple Sclerosis Research - 23 hours ago]
Hope for 'cheap' hepatitis drug [Published Calcutta Telegraph - Sep 16 2014]
Access to new drugs could save 350 lives from h... [Published Irish Examiner - Sep 16 2014]
The Effects of Interferon/Ribavirin Therapy on ... [Published National AIDS Treatment Advocacy Project - Sep 16 2014]
The Downfall of Pharmaceutical Innovation [Published Georgetown University Hoya - Sep 15 2014]
Gilead mulls price of next version of Sovaldi a... [Published San Francisco Chronicle - Sep 15 2014]
LT recipients with HCV met SVR with telaprevir,... [Published Orthopedics Today - Sep 15 2014]
“Too many” with haemophilia in Ireland have died [Published TheJournal.ie - Sep 15 2014]
Altered cellular and humoral immunity to varice... [Published Arthritis & Rheumatism - Sep 15 2014]
Long live peptides evolution of peptide half-li... [Published Drug Discovery World - Sep 15 2014]
Interferon-Gamma Assay in Combination with Tube... [Published Plosone.org - Sep 15 2014]
Health Column: Should we be concerned about Ebo... [Published Glenwood Independent - Sep 15 2014]
Modification of T Cells to Target CS1 Improves ... [Published The ASCO Post - Sep 15 2014]
Gilead’s New Hepatitis C Drug Will Cost More [Published American Journal of Managed Care - Sep 15 2014]
Gilead Inks Generic Licensing Agreements for He... [Published Genetic Engineering News - Sep 15 2014]
Balky payers, beware: Gilead eyes $95K-or-so pr... [Published FiercePharma - Sep 15 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
DNAtrix Announces Treatment Of First Patient Wi... [Published PR Newswire: Health - 16 hours ago]
HOUSTON, Sept. 16, 2014 /PRNewswire/ -- DNAtrix, Inc., experts in oncolytic virus development, today announced that the first patient was treated with the company's lead product, DNX-2401, a replication competent adenovirus plus gamma interferon in a ...
Update on Alnylam (And the Direction of Things ... [Published In the Pipeline - 18 hours ago]
Here's a look from Technology Review at the resurgent fortunes of Alnylam and RNA interference (which I blogged about here ). But now Alnylam is testing a drug to treat (familial amyloid polyneuropathy) in advanced human trials. It’s the last ...
Daclizumab HYP a new kid on the block [Published Multiple Sclerosis Research - 23 hours ago]
Othman AA, Tran JQ, Tang MT, Dutta S. Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers: Integrated Analysis of Intravenous and Subcutaneous, Single- and Multiple-Dose Administration.  Clin Pharmacokinet. 2014 Sep 12. ...
Increased risk of bipolar disorder and depressi... [Published Multiple Sclerosis Research - Sep 15 2014]
This is an interesting study conducted using the Swedish National Patient Register looking at the risk of developing MS in patients with psychiatric disorders. The paper showed that patients with depression and bipolar disorder are more likely to develop ...
ACTRIMS/ECTRIMS 2014 – Part 1 [Published MSology - Sep 11 2014]
Update on oral therapies Gilenya Tecfidera Aubagio Drug vs. drug The annual congress of the European Committee on Treatment and Research in MS (ECTRIMS), held this year in conjunction with the Americas Committee (ACTRIMS), is the largest ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Hemispherx Biopharma and Bioclones Join Forces ... [Published GlobeNewswire: Acquisitions News - Jul 08 2014]
Simeprevir has now been approved in Russia [Published GlobeNewswire: Acquisitions News - Mar 24 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.